Review
Version 1
This version is not peer-reviewed
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
Version 1
: Received: 3 February 2019 / Approved: 4 February 2019 / Online: 4 February 2019 (17:01:31 CET)
A peer-reviewed article of this Preprint also exists.
Rinnerthaler, G.; Gampenrieder, S.P.; Greil, R. HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer. Int. J. Mol. Sci. 2019, 20, 1115. Rinnerthaler, G.; Gampenrieder, S.P.; Greil, R. HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer. Int. J. Mol. Sci. 2019, 20, 1115.
Journal reference: Int. J. Mol. Sci. 2019, 20, 1115
DOI: 10.3390/ijms20051115
Abstract
Since the discovery of the human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers and the development of HER2 directed therapies, the prognosis of HER2 amplified breast cancers has increased meaningfully. Next to monoclonal anti-HER2 antibodies and tyrosine kinase inhibitors, the antibody-drug conjugate T-DM1 is a pillar of targeted treatment of advanced HER2-positive breast cancers. Currently, several HER2 directed antibody-drug conjugates are under clinical investigation for HER2 amplified but also HER2 expressing but not amplified breast tumors. In this article, we review the current preclinical and clinical evidence of the investigational drugs A166, ALT-P7, ARX788, DHES0815A, DS-8201a, RC48, SYD985, MEDI4276 and XMT-1522.
Subject Areas
ADC; HM2-MMAE; (vic-)trastuzumab duocarmazine; Trastuzumab deruxtecan; TAK-522; Trastuzumab emtansine; anti-HER2/PBD-MA; HER2 low; HER2-low; mode of action
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Readers' Comments and Ratings (0)
Send a private comment to the author(s)